Avalo Therapeutics, Inc.AVTXNASDAQ
Loading
Year-over-year free cash flow growth rate
Percentile
P28
Within normal range
vs 3Y Ago
-0.3x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -43.68% |
| Q2 2025 | -20.44% |
| Q1 2025 | 37.14% |
| Q4 2024 | -30.51% |
| Q3 2024 | 29.21% |
| Q2 2024 | -162.54% |
| Q1 2024 | -112.11% |
| Q4 2023 | 57.23% |
| Q3 2023 | 38.00% |
| Q2 2023 | -9.69% |
| Q1 2023 | -151.55% |
| Q4 2022 | -170.27% |
| Q3 2022 | 145.40% |
| Q2 2022 | 22.04% |
| Q1 2022 | 6.10% |
| Q4 2021 | -4.51% |
| Q3 2021 | 14.68% |
| Q2 2021 | -4.64% |
| Q1 2021 | -27.56% |
| Q4 2020 | -20.47% |
| Q3 2020 | -39.50% |
| Q2 2020 | -49.05% |
| Q1 2020 | -241.52% |
| Q4 2019 | 77.95% |
| Q3 2019 | -11.93% |
| Q2 2019 | -107.09% |
| Q1 2019 | -32.83% |
| Q4 2018 | -328.59% |
| Q3 2018 | -69.66% |
| Q2 2018 | -13.59% |
| Q1 2018 | 88.50% |
| Q4 2017 | -113.64% |
| Q3 2017 | 1190.16% |
| Q2 2017 | 22.04% |
| Q1 2017 | 39.62% |
| Q4 2016 | -8.19% |
| Q3 2016 | 7.76% |
| Q2 2016 | -0.39% |
| Q1 2016 | 84.21% |
| Q4 2015 | -1182.52% |